Evidera

Commercial

Javier Cid - Chief Investigator - EvideraIncAlison Booth - Corresponding Applicant - EvideraIncMickael Hiligsmann - Collaborator - Maastricht UniversityMireia Raluy Callado - Collaborator - EvideraIncNoami Berfeld - Collaborator - EvideraIncPhilip Conaghan - Collaborator - University of LeedsRavi Iyer - Collaborator - Teva Pharmaceuticals LtdRobert Donaldson - Collaborator - EvideraIncSangtaeck Lim - Collaborator - Teva Pharmaceuticals LtdTahir Saleem - Collaborator - Teva Pharmaceuticals Ltd

CPRD697

Osteoarthritis is a painful disease of the knees, hips and other joints in the body. About 10% of UK adults have osteoarthritis, which often gets worse over time. We don’t yet know how to stop osteoarthritis getting worse. So, we treat it by replacing the affected joint or by using medicines to reduce pain. There is not a lot of published information available to help understand the economic impacts to healthcare systems that osteoarthritis may have.

Osteoarthritis (OA) is a degenerative joint disease affecting the cartilage and surrounding tissues. In the United Kingdom (UK), approximately 10% of adults have symptomatic and clinically diagnosed OA, with knee OA being the most common. There are no current treatments available to stop or slow OA progression, hence pharmacological management of OA patients focuses on symptom management (i.e. analgesics for pain), with minimal impact on the underlying disease. Published data on estimated direct and indirect costs of OA in the UK are limited, suggesting that more research into this area is imperative to understand burden of OA in the UK

18/03/2021

Release